| Outcome Measures: |
Primary: Percentage of Participants Achieving Good Glycemic Control (Reduction in Fasting Blood Glucose Level < 130 mg/dL), The reported data were percentage of participants who achieved good glycemic control at 48 Week. Good glycemic control was defined with fasting blood glucose level \< 130 mg/dL., 48 Week|Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.9 %), The reported data were percentage of participants who achieved good glycemic control at 48 Week. Good glycemic control was defined with HbA1c (NGSP) Values \< 6.9 %., 48 Week|Changes From Baseline in Laboratory Parameters (Systolic Blood Pressure (SBP)) at 48 Week, Changes from baseline in laboratory parameter at 48 Week were reported. The reported data on this outcome measure is SBP as a one of laboratory parameters., From Baseline, Up to 48 Week|Changes From Baseline in Laboratory Parameters (Diastolic Blood Pressure (DBP)) at 48 Week, Changes from baseline in laboratory parameter at 48 Week were reported. The reported data on this outcome measure is DBP as a one of laboratory parameters., From Baseline, Up to 48 Week|Changes From Baseline in Laboratory Parameters (High-Density Lipoprotein Cholesterol (HDL-Cholesterol)) at 48 Week, Changes from baseline in laboratory parameter at 48 Week were reported. The reported data on this outcome measure is HDL-Cholesterol as a one of laboratory parameters., From Baseline, Up to 48 Week|Changes From Baseline in Laboratory Parameters (Low-Density Lipoprotein Cholesterol (LDL-Cholesterol)) at 48 Week, Changes from baseline in laboratory parameter at 48 Week were reported. The reported data on this outcome measure is LDL-Cholesterol as a one of laboratory parameters., From Baseline, Up to 48 Week|Changes From Baseline in Glycosylated Hemoglobin (HbA1c) at 48 Week in Participants Stratified by Dose of Pioglitazone, The reported data were changes from baseline in laboratory parameter, that is HbA1c (National Glycohemoglobin Standardization Program Criteria; NGSP), at 48 Week in participants stratified by specific characteristics, mean daily dose of pioglitazone, at the time of enrollment. Mean daily dose of pioglitazone at the time of enrollment were categorized into \<15 mg, 15 to \<30 mg, 30 \<45 mg and 45 mg ≤ as planned (Note; final categorized number of participants was 0 in 45 mg ≤ group)., From Baseline, Up to 48 Week|Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Levels of HbA1c, The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, Levels of HbA1c, at the time of enrollment. Levels of HbA1c at the time of enrollment were categorized into \<6.2%, 6.2 to \<6.9%, 6.9 \<7.4%, 7.4 \<8.4%, and 8.4% ≤ as planned (Note; final categorized number of participants was 0 in \<6.2% and 6.2 to \<6.9% group)., From Baseline, Up to 48 Week|Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Gender, The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, Gender, at the time of enrollment. Gender was categorized into male and female., From Baseline, Up to 48 Week|Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Levels of BMI, The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, Levels of BMI, at the time of enrollment. Levels of BMI at the time of enrollment were categorized into \<18.5 kg/m\^2, 18.5 to \<25 kg/m\^2, 25 \<30 kg/m\^2, and 30 kg/m\^2 ≤., From Baseline, Up to 48 Week|Changes From Baseline in HbA1c at 48 Week in Participants Stratified by Presence of Companion Anti-Diabetes Drugs, The reported data were changes from baseline in laboratory parameter, that is HbA1c (NGSP), at 48 Week in participants stratified by specific characteristics, presence of companion anti-diabetes drugs, at the time of enrollment. Presence of companion anti-diabetes drugs at the time of enrollment were categorized into Had presence of companion anti-diabetes drugs and Had no presence of companion anti-diabetes drugs., From Baseline, Up to 48 Week|Blood Glucose-Related Laboratory Parameters (Fasting Blood Glucose Level) at Each Time Point, Fasting blood glucose level at baseline and 48 Week were reported as one of blood glucose-related laboratory parameters., Baseline and 48 Week|Blood Glucose-Related Laboratory Parameters (HbA1c Values) at Each Time Point, HbA1c (NGSP) values at baseline and 48 Week were reported as one of blood glucose-related laboratory parameters., Baseline and 48 Week | Secondary: Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs), ADRs are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment. AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug., Up to 48 Weeks
|
